These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38621343)

  • 21. Comparison of Long-term Survival of Patients With Early-Stage Non-Small Cell Lung Cancer After Surgery vs Stereotactic Body Radiotherapy.
    Chi A; Fang W; Sun Y; Wen S
    JAMA Netw Open; 2019 Nov; 2(11):e1915724. PubMed ID: 31747032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort.
    Soldà F; Lodge M; Ashley S; Whitington A; Goldstraw P; Brada M
    Radiother Oncol; 2013 Oct; 109(1):1-7. PubMed ID: 24128806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer.
    Phillips I; Sandhu S; Lüchtenborg M; Harden S
    Clin Oncol (R Coll Radiol); 2019 Oct; 31(10):681-687. PubMed ID: 31377081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study.
    Ricardi U; Frezza G; Filippi AR; Badellino S; Levis M; Navarria P; Salvi F; Marcenaro M; Trovò M; Guarneri A; Corvò R; Scorsetti M
    Lung Cancer; 2014 Jun; 84(3):248-53. PubMed ID: 24681279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
    Palma DA; Nguyen TK; Louie AV; Malthaner R; Fortin D; Rodrigues GB; Yaremko B; Laba J; Kwan K; Gaede S; Lee T; Ward A; Warner A; Inculet R
    JAMA Oncol; 2019 May; 5(5):681-688. PubMed ID: 30789648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis.
    Paul S; Lee PC; Mao J; Isaacs AJ; Sedrakyan A
    BMJ; 2016 Jul; 354():i3570. PubMed ID: 27400862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of stereotactic body radiotherapy versus lobectomy for stage I non-small cell lung cancer: a propensity score matching analysis.
    Lin Q; Sun X; Zhou N; Wang Z; Xu Y; Wang Y
    BMC Pulm Med; 2019 May; 19(1):98. PubMed ID: 31118007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Lung Parenchymal-Only Failure on Overall Survival in Early-Stage Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy.
    Elbanna M; Shiue K; Edwards D; Cerra-Franco A; Agrawal N; Hinton J; Mereniuk T; Huang C; Ryan JL; Smith J; Aaron VD; Burney H; Zang Y; Holmes J; Langer M; Zellars R; Lautenschlaeger T
    Clin Lung Cancer; 2021 May; 22(3):e342-e359. PubMed ID: 32736936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgery or radiotherapy for stage I lung cancer? An intention-to-treat analysis.
    Spencer KL; Kennedy MPT; Lummis KL; Ellames DAB; Snee M; Brunelli A; Franks K; Callister MEJ
    Eur Respir J; 2019 Jun; 53(6):. PubMed ID: 30635294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
    Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
    Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
    Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
    Jacobs CD; Mehta K; Gao J; Wang X; Salama JK; Kelsey CR; Torok JA
    Clin Lung Cancer; 2022 Mar; 23(2):177-184. PubMed ID: 34301453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The management of stage I Non-Small cell lung cancer (NSCLC) in Ontario: A Population-Based study of patterns of care and Stereotactic Ablative Body radiotherapy (SABR) utilization from 2010 to 2019.
    Ashworth A; Kong W; Owen T; Hanna TP; Brundage M
    Radiother Oncol; 2024 May; 194():110153. PubMed ID: 38364940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly.
    Shirvani SM; Jiang J; Chang JY; Welsh JW; Gomez DR; Swisher S; Buchholz TA; Smith BD
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1060-70. PubMed ID: 22975611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
    Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: results from propensity score analysis.
    Mokhles S; Verstegen N; Maat AP; Birim Ö; Bogers AJ; Mokhles MM; Lagerwaard FJ; Senan S; Takkenberg JJ
    Lung Cancer; 2015 Mar; 87(3):283-9. PubMed ID: 25622781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Video-assisted thoracic lobectomy
    Detillon DDEMA; Aarts MJ; De Jaeger K; Van Eijck CHJ; Veen EJ
    Eur Respir J; 2019 Jun; 53(6):. PubMed ID: 30923188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC).
    Palma DA; Nguyen TK; Kwan K; Gaede S; Landis M; Malthaner R; Fortin D; Louie AV; Frechette E; Rodrigues GB; Yaremko B; Yu E; Dar AR; Lee TY; Gratton A; Warner A; Ward A; Inculet R
    Radiat Oncol; 2017 Jan; 12(1):30. PubMed ID: 28129789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
    Lee S; Song SY; Kim SS; Choi W; Je HU; Back GM; Cho B; Jeong SY; Choi EK
    Clin Lung Cancer; 2018 Mar; 19(2):e253-e261. PubMed ID: 29196082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stereotactic body radiotherapy or stereotactic ablative radiotherapy versus surgery for patients with T1-3N0M0 non-small cell lung cancer: a systematic review and meta-analysis.
    Li M; Yang X; Chen Y; Yang X; Dai X; Sun F; Zhang L; Zhan C; Feng M; Wang Q
    Onco Targets Ther; 2017; 10():2885-2892. PubMed ID: 28652770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.